Sanofi ADR
FREURSanofi ADR (MI:1SAN) — Biotechnology: Pharmaceutical Preparations. Número de bolsas en las que cotizan las acciones de la empresa: 6. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la Empresa
- Sitio Web
- sanofi.com
- Relaciones con los Inversores
- sanofi.com/en/investors
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede Central
- PARIS, France
- Gestión
- Paul Hudson
- Últimos Informes
- Empleados
- 106 566
- Fundada
- 2004
- Cotiza Desde
- 24.07.2006 (MI:1SAN)
- Acciones en Circulación
- 1.22 mil M a 2025-12-31
- Capital Flotante
- 2.16 mil M
- Capitalización Bursátil
- 98.67 mil M USD
- Insiders
- 0%
- Inversores Institucionales
- 8.02%
- Industria (SIC)
- Pharmaceutical Preparations
- Forma Jurídica
- QVPB
- ISIN
- FR0000120578
- LEI
- 549300E9PC51EN656011
- P/E
- 22.8
- P/B
- 1.27
- Ratio de Reparto
- ≈64.0%
- FCF
- 10.8 mil M EUR
- Pagos / FCF
- 47%
- Deuda
- 18.7 mil M EUR1.0 a. de FCF
- Racha de Dividendos
- 23 a.
- Beneficios, FCF y dividendos pagados — para los 12 meses hasta 31.12.2025 (el último informe de la compañía).
- NAV
Descripción
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Bolsas y Tickers
| Bolsa | Ticker | Moneda | Precio | Tipo |
|---|---|---|---|---|
| PA Euronext Paris | SAN principal | EUR | 74.12 -1.11% | acciones ordinarias |
| LSE London Stock Exchange | 0O59 IOB | EUR | 71.63 +0.72% | acciones ordinarias |
| MI Borsa Italiana (Milan) | 1SAN secundaria | EUR | 74.24 -0.88% | acciones ordinarias |
| US USA Stocks | SNYNF OTC | USD | 81.65 -0.80% | acciones ordinarias |
| VI Vienna Stock Exchange | SANO secundaria | EUR | 71.3 +1.03% | acciones ordinarias |
| XETRA Xetra | SNW secundaria | EUR | 71.78 -1.21% | acciones ordinarias |
Dividendos
Sanofi ADR (1SAN) paga dividendos una vez al año. Por año (12 meses hasta e incluyendo el último pago anunciado): 4.12 EUR por acción (pagos: 1). Eso representa aproximadamente el 5.55% del precio actual de la acción. Según el historial de pagos, se espera la próxima fecha ex-dividendo alrededor de 04.05.2027. Historial de dividendos ininterrumpido: 23 años.
| Fecha Ex | Pago | Importe | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-05-05 | 2026-05-07 | 4.1200 EUR | 5.3/5.3 % | anual | MI:1SAN |
| 2025-05-12 | 2025-05-14 | 3.9200 EUR | 4.2/4.2 % | anual | MI:1SAN |
| 2024-05-13 | 2024-05-15 | 3.7600 EUR | 4.0/4.0 % | anual | MI:1SAN |
| 2023-05-30 | — | 3.5600 EUR | 3.6/3.6 % | anual | MI:1SAN |
| 2022-05-06 | — | 3.3300 EUR | 3.3/3.3 % | anual | MI:1SAN |
Principales Accionistas
| Titular | Participación | Acciones | Fecha del Informe |
|---|---|---|---|
| Dodge & Cox Inc. | 10.54% | 28.09 M | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 7.84% | 20.9 M | 2026-06-30 |
| Morgan Stanley | 4.02% | 10.7 M | 2026-06-30 |
| Fisher Asset Management,… | 3.99% | 10.63 M | 2026-06-30 |
| Bank of America Corporat… | 3% | 8.01 M | 2026-06-30 |
| Invesco Ltd. | 2.55% | 6.8 M | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.47% | 6.57 M | 2026-06-30 |
| Mondrian Investment Part… | 2.07% | 5.52 M | 2026-06-30 |
| Brandes Investment Partn… | 1.55% | 4.14 M | 2026-06-30 |
| AIM Sector Funds (Invesc… | 1.51% | 4.03 M | 2026-04-30 |
| Federated Hermes, Inc. | 1.44% | 3.85 M | 2026-06-30 |
| Boston Partners | 1.44% | 3.84 M | 2026-06-30 |
| VANGUARD STAR FUNDS-Vang… | 1.31% | 15.85 M | 2026-07-31 |
| Putnam ETF Trust-Putnam… | 1.26% | 3.36 M | 2026-05-31 |
| VANGUARD TAX-MANAGED FUN… | 0.87% | 10.53 M | 2026-06-30 |
| iShares Trust-iShares Co… | 0.67% | 8.11 M | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.63% | 1.67 M | 2026-06-30 |
| AMERICAN MUTUAL FUND | 0.59% | 1.58 M | 2026-06-30 |
| American Century Capital… | 0.37% | 976 561 | 2026-06-30 |
| Bridge Builder Trust-Bri… | 0.36% | 967 100 | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 4.24 M | 2026-07-31 |
| VanEck ETF Trust-VanEck… | 0.35% | 938 561 | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.33% | 4.04 M | 2026-06-30 |
| iShares Trust-iShares MS… | 0.32% | 3.89 M | 2026-08-31 |
| Capital World Growth & I… | 0.3% | 3.67 M | 2026-06-30 |
| -Victory Pioneer Core Eq… | 0.3% | 799 487 | 2026-06-30 |
| Fidelity Covington Trust… | 0.3% | 797 184 | 2026-08-31 |
| NEW PERSPECTIVE FUND | 0.29% | 3.56 M | 2026-06-30 |
| Federated Hermes Eqy. Fd… | 0.29% | 3.48 M | 2026-07-31 |
| Bridge Builder Trust-Bri… | 0.29% | 3.44 M | 2026-06-30 |
| Pacer Advisors, Inc. | 0.1% | 1.16 M | 2026-06-30 |
| Generali Investments Cee… | 0% | 29 339 | 2026-06-30 |
| Paradigm Asset Managemen… | 0% | 19 200 | 2026-06-30 |
| Gamma Investing LLC | 0% | 58 | 2026-06-30 |
| L'Oréal | — | — | — |
